Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
Backed by an $8.4 billion international licensing deal with Bristol Myers Squibb, Biokin’s groundbreaking dual-target therapy…
Latest
- Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
- Basic Semiconductor adds to growing list of Tsinghua startups tapping Hong Kong IPO market
- China’s memory chip champion CXMT set for record-breaking Shanghai IPO
- Ant Group tackles robotic blind spots as the humanoid market faces a reality check
- Beyond the chatbot: Shanghai AI summit highlights global race to solve hardware and robotics bottlenecks
